Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II YM155 monotherapy in previously treated advanced non-small cell lung cancer
2005-000914-11Phase 2Completed
- Sponsor
- Astellas
- Start
- Aug 2005
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sepantronium in non-small cell lung cancer (NSCLC), sponsored by Astellas. Primary endpoint: Objective tumor response rate. Started Aug 2005; status: completed.
02
Drugs
sepantronium
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-000914-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000914-11.